Emmett Cunningham Net Worth

Emmett Cunningham biography

Dr. Emmett T. Cunningham Jr., M.D. Ph.D. serves as Director of the Company. Dr. Cunningham is a Senior Managing Director in the Blackstone Life Sciences, a life sciences investment firm, having joined Blackstone as part of its acquisition of Clarus in December 2018. He joined Clarus in 2006. From February 2004 to December 2005, he was Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., a pharmaceutical company. From April 2002 to February 2004, Dr. Cunningham was Vice President of Clinical Research Development and Licensing. Dr. Cunningham is also Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine and the co-founder and Chair of the Ophthalmology Innovation Summit. Dr. Cunningham serves on the boards of directors of Annexon Biosciences, Graybug Vision, SFJ Pharmaceuticals Group and Lumos Pharma Inc. and he serves on the Scientific Advisory Board of Aerie Pharmaceuticals, Inc. He previously served as the Chair of the board of directors of Restoration Robotics. Dr. Cunningham received a B.S. from Drexel University, a B.A., M.D. and M.P.H. from Johns Hopkins University and a Ph.D. in neuroscience from the University of California at San Diego. Cunningham is qualified to serve on our Board of Directors due to his experience in research and investing in life science companies.

What is the salary of Emmett Cunningham?

As the Director of Galera Therapeutics Inc, the total compensation of Emmett Cunningham at Galera Therapeutics Inc is $178,160. There are 10 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.

How old is Emmett Cunningham?

Emmett Cunningham is 59, he's been the Director of Galera Therapeutics Inc since 2018. There are 11 older and 5 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.

What's Emmett Cunningham's mailing address?

Emmett's mailing address filed with the SEC is C/O CLARUS VENTURES, 314 MAIN ST., 15TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Galera Therapeutics Inc

Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ..., and Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.

What does Galera Therapeutics Inc do?

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Galera Therapeutics Inc executives and stock owners

Galera Therapeutics Inc executives and other stock owners filed with the SEC include:

• J. Mel Sorensen,
  President, Chief Executive Officer, Director
• Christopher Degnan,
  Chief Financial Officer
• Robert Beardsley,
  Chief Operating Officer
• Dr. J. Mel Sorensen,
  CEO, Pres & Director
• Christopher Degnan,
  CFO & Sec.
• Dr. Robert A. Beardsley,
  Co-Founder & COO
• Arthur Fratamico,
  Chief Business Officer
• Jon Holmlund,
  Chief Medical Officer
• Lawrence Alleva,
  Independent Director
• Michael Powell,
  Independent Chairman of the Board
• Emmett Cunningham,
  Director
• Kevin Lokay,
  Independent Director
• Linda West,
  Independent Director
• Joel Sussman,
  Chief Accounting Officer
• Mark J. Bachleda M.B.A., Pharm.D.,
  Chief Commercial Officer
• Arthur J. Fratamico,
  Chief Bus. Officer
• Dr. Jon T. Holmlund,
  Chief Medical Officer
• Jennifer Evans Stacey Esq.,
  Chief Legal & Compliance Officer and Sec.
• Dr. Dennis P. Riley Ph.D.,
  Chief Scientific Officer
• Joel F. Sussman,
  Chief Accounting Officer & Treasurer
• Bioventures Ltd Novartis Ag...,
  
• Chris Degnan,
  Chief Financial Officer
• Jason Fuller,
  Director
• Iv A, L.P.Clarus Iv B, L.P....,
  
• Group Inc Blackstone Group ...,
  
• Clarus Gp L.P.Blackstone Cl...,
  
• Enterprise Associates 14, L...,
  
• Venture Partners Ix, L.P.So...,
  
• Dennis Riley,
  Chief Scientific Officer
• Holdings A/S Novo,
  10% owner
• Mark Bachleda,
  Chief Commercial Officer
• Jennifer Evans Stacey,
  See Remarks
• Yair Schneid,
  10% owner
• Eugene P. Kennedy,
  Chief Medical Officer
• Mel Sorensen,
  President and CEO